SEGMENT INFORMATION (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($) segment	Dec. 31, 2023 USD ($)
Segment Reporting [Abstract]
Number of operating segments | segment	1
Number of reportable segments | segment	1
Segment Reporting Information [Line Items]
Revenues	$ 501	$ 424
Operating expenses
Research and development	30,946	16,307
General and administrative	13,192	13,375
Operating loss	(43,637)	(29,258)
Income tax expense	4	0
Loss from continuing operations	(39,807)	(27,872)
Net loss	(39,834)	(28,452)
Reportable Segment
Operating expenses
Other segment items	3,413	2,944
General and administrative	13,192	13,375
Total operating expenses	44,138	29,682
Operating loss	(43,637)	(29,258)
Other income, net	3,834	1,386
Loss from continuing operations before income taxes	(39,803)	(27,872)
Income tax expense	4	0
Loss from continuing operations	(39,807)	(27,872)
Loss from discontinued operations, net of income taxes	(27)	(580)
Net loss	(39,834)	(28,452)
Reportable Segment | Royalty revenues
Segment Reporting Information [Line Items]
Revenues	501	424
Reportable Segment | Repibresib (VYN201)
Operating expenses
Research and development	16,271	4,593
Reportable Segment | VYN202
Operating expenses
Research and development	$ 11,262	$ 8,770